ACTH therapy and VILIP-1 concentrations in West syndrome-Can we predict a treatment prognosis?-
| Project/Area Number |
26860356
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
HOSHIDE Madoka 山口大学, 医学部附属病院, 助教 (30610878)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | West症候群 / VILIP-1 / 発達遅滞 / Visinin like protein 1 / ACTH療法 / 難治てんかん / MAP2 / キノリン酸 |
|---|
| Outline of Final Research Achievements |
Aim:In approximately ACTH therapy for West syndrome, we studied the marker for the treatment prognostic value.Method:26 infants that West syndrome was registered in the report of the past clinical condition study in our group. We did West syndrome with infants diagnosed by findings clinically with electroencephalogram with spasm and compatibility. The control group was the infant with benign infantile spasms considered that a neurologic prognosis is normal. We measured VILIP-1 concentrations, MAP2 concentrations, quinolinic acid concentrations in approximately ACTH therapy. Results:VILIP-1 concentrations, MAP2 concentrations, quinolinic acid concentrations in West syndrome, did not increased. Discussion: For the nervous disorde in West syndrome, it becomes VILIP-1, MAP2, none of the quinolinic acid with the marker.
|
Report
(3 results)
Research Products
(12 results)
